Definium Therapeutics presents pre-clinical safety data on new psychedelic treatment at APA meeting

Definium Therapeutics presents pre-clinical safety data on new psychedelic treatment at APA meeting
Definium details safety at APA event

Definium Therapeutics presented scientific posters featuring pre-clinical safety data for its investigational psychedelic treatment at the American Psychiatric Association (APA) Annual Meeting.

The company aims to advance its pioneering work in psychedelic-based therapies, highlighting its commitment to innovation in mental health treatment. Attendees at the APA event were given a deeper view into Definium Therapeutics research contributions and ongoing development efforts in this emerging field.

Definium Therapeutics recently reported Q1 2026 financial results, highlighting ongoing momentum in advancing mental health treatment initiatives (see report). Earlier this year, the company began dosing patients in Ascend, its second Phase 3 pivotal trial targeting major depressive disorder (trial details). The company remains focused on research and development in psychiatric care.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.